Lamotrigine

Highest phase reached

Approved

www.ebi.ac.uk

Drug type

Small molecule

www.ebi.ac.uk

First approval year

1994

www.ebi.ac.uk

First approval year: 1994
www.ebi.ac.uk

Listing at source: Listed

Highest phase reached: Approved
www.ebi.ac.uk

Drug type: Small molecule
www.ebi.ac.uk

Drug name: Lamotrigine
www.ebi.ac.uk

Molecular weight: 256.1
www.ebi.ac.uk

Structure (SMILES): Nc1nnc(-c2cccc(Cl)c2Cl)c(N)n1
www.ebi.ac.uk

lamictal
Lamictal
lamictal cd
Lamictal cd
lamictal odt
Lamictal odt
lamictal xr
Lamictal xr
lamotrigine
Lamotrigine

1 2 4 triazine 3 5 diamine 6 2 3 dichlorophenyl
1,2,4-TRIAZINE-3,5-DIAMINE, 6-(2,3-DICHLOROPHENYL)
3 5 diamino 6 2 3 dichlorophenyl as triazine
3,5-Diamino-6-(2,3-dichlorophenyl)-as-triazine
bw 430c
BW 430C
BW-430C
BW430C (lamotrigine)
bw430c lamotrigine
lamictal
Lamictal
Lamictal (lamotrigine)
lamictal extended release
lamictal lamotrigine
lamictal tablets 25 mg
Lamictal®
Lamictal® Tablets 25 mg
lamotrigina
Lamotrigina
lamotrigine
Lamotrigine
lamotrigine (brand Lamictal)
Lamotrigine (brand name vs generic drugs)
Lamotrigine (drug)
Lamotrigine (Drug)

And 59 more, listed on the interactive page.

ATC classification codes

N03AX09

Sources for recorded values

www.ebi.ac.uk

CAS registry numbers

84057-84-1

ChEMBL ID: CHEMBL741
www.ebi.ac.uk

InChIKey: PYZRQGJRPPTADH-UHFFFAOYSA-N
www.ebi.ac.uk

PubChem compound IDs

3878

RxNorm IDs (RxCUI)

28439

FDA ingredient codes (UNII)

U3H27498KS

Applicant: GLAXOSMITHKLINE LLC
Approval date: 27 Dec 1994
Application number: NDA020241

Patents: 3
Designations: 2
Earliest recorded loss of exclusivity: 29 May 2040
First in class: No
Fast track: No
Breakthrough designation: No
Orphan designation: No
Priority review: Yes
Orphan exclusivity: No
Accelerated approval: No
Availability: Prescription only
Boxed warning: Yes

United States (FDA): Approved

Pharmacology name: lamotrigine
Type: Synthetic organic
Drug name stem: -trigine
Approval recorded by Guide to Pharmacology: Yes

Administration routes

Oral

Mechanism
Sodium channel alpha subunit blocker
Action type
Blocker
Target
Sodium channel alpha subunit
Protein identifier
P35498
Mechanism
Sodium channel alpha subunit blocker
Action type
Blocker
Target
Sodium channel alpha subunit
Protein identifier
P35499
Mechanism
Sodium channel alpha subunit blocker
Action type
Blocker
Target
Sodium channel alpha subunit
Protein identifier
Q01118
Mechanism
Sodium channel alpha subunit blocker
Action type
Blocker
Target
Sodium channel alpha subunit
Protein identifier
Q14524
Mechanism
Sodium channel alpha subunit blocker
Action type
Blocker
Target
Sodium channel alpha subunit
Protein identifier
Q15858
Mechanism
Sodium channel alpha subunit blocker
Action type
Blocker
Target
Sodium channel alpha subunit
Protein identifier
Q99250
Mechanism
Sodium channel alpha subunit blocker
Action type
Blocker
Target
Sodium channel alpha subunit
Protein identifier
Q9NY46
Mechanism
Sodium channel alpha subunit blocker
Action type
Blocker
Target
Sodium channel alpha subunit
Protein identifier
Q9UI33
Mechanism
Sodium channel alpha subunit blocker
Action type
Blocker
Target
Sodium channel alpha subunit
Protein identifier
Q9UQD0
Mechanism
Sodium channel alpha subunit blocker
Action type
Blocker
Target
Sodium channel alpha subunit
Protein identifier
Q9Y5Y9

Open Targets mechanisms

Mechanism
Sodium channel alpha subunit blocker
Action type
Blocker
Target
Sodium channel alpha subunit

Action type
Blocker
Gene symbol
SCN1A
Protein identifier
P35498
Organism
Homo sapiens
Target development level
Clinical
Action type
Blocker
Gene symbol
SCN4A
Protein identifier
P35499
Organism
Homo sapiens
Target development level
Clinical
Action type
Blocker
Gene symbol
SCN5A
Protein identifier
Q14524
Organism
Homo sapiens
Target development level
Clinical
Action type
Blocker
Gene symbol
SCN9A
Protein identifier
Q15858
Organism
Homo sapiens
Target development level
Clinical
Action type
Blocker
Gene symbol
SCN2A
Protein identifier
Q99250
Organism
Homo sapiens
Target development level
Clinical
Action type
Blocker
Gene symbol
SCN3A
Protein identifier
Q9NY46
Organism
Homo sapiens
Target development level
Clinical
Action type
Blocker
Gene symbol
SCN8A
Protein identifier
Q9UQD0
Organism
Homo sapiens
Target development level
Clinical
Action type
Blocker
Gene symbol
SCN10A
Protein identifier
Q9Y5Y9
Organism
Homo sapiens
Target development level
Clinical

Condition
Epilepsy
Highest recorded phase
4
Condition identifier
EFO:0000474
Subject identifier
D004827
Condition
Mental Disorders
Highest recorded phase
1
Condition identifier
EFO:0000677
Subject identifier
D001523
Condition
HIV Infections
Highest recorded phase
1
Condition identifier
EFO:0000764
Subject identifier
D015658
Condition
Obesity
Highest recorded phase
3
Condition identifier
EFO:0001073
Subject identifier
D009765
Condition
Cocaine-Related Disorders
Highest recorded phase
2
Condition identifier
EFO:0002610
Subject identifier
D019970
Condition
Fasting
Highest recorded phase
1
Condition identifier
EFO:0002756
Subject identifier
D005215
Condition
Peripheral Nervous System Diseases
Highest recorded phase
3
Condition identifier
EFO:0003100
Subject identifier
D010523
Condition
Pain
Highest recorded phase
3
Condition identifier
EFO:0003843
Subject identifier
D010146
Condition
Substance-Related Disorders
Highest recorded phase
2
Condition identifier
EFO:0003890
Subject identifier
D019966
Condition
Multiple Sclerosis, Relapsing-Remitting
Highest recorded phase
2
Condition identifier
EFO:0003929
Subject identifier
D020529
Condition
Mood Disorders
Highest recorded phase
3
Condition identifier
EFO:0004247
Subject identifier
D019964
Condition
Epilepsies, Partial
Highest recorded phase
4
Condition identifier
EFO:0004263
Subject identifier
D004828
Condition
Feeding and Eating Disorders
Highest recorded phase
3
Condition identifier
EFO:0005203
Subject identifier
D001068
Condition
Anxiety
Highest recorded phase
3
Condition identifier
EFO:0005230
Subject identifier
D001007
Condition
Opioid-Related Disorders
Highest recorded phase
2
Condition identifier
EFO:0005611
Subject identifier
D009293
Condition
Epilepsy, Tonic-Clonic
Highest recorded phase
4
Condition identifier
EFO:0007262
Subject identifier
D004830
Condition
Multiple Sclerosis, Chronic Progressive
Highest recorded phase
2
Condition identifier
EFO:0008522
Subject identifier
D020528
Condition
Bipolar Disorder
Highest recorded phase
4
Condition identifier
EFO:0009963
Subject identifier
D001714
Condition
Dementia
Highest recorded phase
3
Condition identifier
HP:0000726
Subject identifier
D003704
Condition
Seizures
Highest recorded phase
4
Condition identifier
HP:0001250
Subject identifier
D012640
Condition
Epilepsy, Tonic-Clonic
Highest recorded phase
4
Condition identifier
HP:0002069
Subject identifier
D004830
Condition
Cognitive Dysfunction
Highest recorded phase
2
Condition identifier
HP:0100543
Subject identifier
D060825
Condition
Depressive Disorder
Highest recorded phase
4
Condition identifier
MONDO:0002009
Subject identifier
D003866
Condition
Depressive Disorder
Highest recorded phase
4
Condition identifier
MONDO:0002050
Subject identifier
D003866
Condition
Bipolar Disorder
Highest recorded phase
4
Condition identifier
MONDO:0004985
Subject identifier
D001714

And 7 more, listed on the interactive page.

Condition identifier
EFO_0000474
Condition identifier
EFO_0000677
Highest recorded phase
1
Condition identifier
EFO_0001073
Highest recorded phase
3
Condition identifier
EFO_0001074
Condition identifier
EFO_0002610
Highest recorded phase
2
Condition identifier
EFO_0002756
Highest recorded phase
1
Condition identifier
EFO_0003890
Condition identifier
EFO_0003929
Highest recorded phase
2
Condition identifier
EFO_0004149
Highest recorded phase
3
Condition identifier
EFO_0004247
Highest recorded phase
3
Condition identifier
EFO_0004263
Condition identifier
EFO_0005203
Highest recorded phase
3
Condition identifier
EFO_0005611
Highest recorded phase
2
Condition identifier
EFO_0007262
Highest recorded phase
3
Condition identifier
EFO_0008522
Highest recorded phase
2
Condition identifier
EFO_0009963
Condition identifier
EFO_0009963
Highest recorded phase
4
Condition identifier
EFO_0009964
Highest recorded phase
3
Condition identifier
EFO_0803536
Highest recorded phase
2
Condition identifier
EFO_1001219
Condition identifier
EFO_1002051
Condition identifier
HP_0001250
Condition identifier
HP_0001250
Highest recorded phase
4
Condition identifier
HP_0002069
Condition identifier
HP_0002069
Highest recorded phase
4

And 39 more, listed on the interactive page.

Warnings

Warning
Black Box Warning
Effect
dermatological toxicity

Open Targets warnings

Warning
Black Box Warning
Effect
dermatological toxicity
Country
United States

Event
abortion spontaneous
Reports
449
Reporting signal score
385.677
Event
aggression
Reports
377
Reporting signal score
306.49
Event
agitation
Reports
502
Reporting signal score
322.812
Event
ataxia
Reports
369
Reporting signal score
579.368
Event
atrial septal defect
Reports
320
Reporting signal score
594.225
Event
coma
Reports
505
Reporting signal score
512.879
Event
convulsion
Reports
884
Reporting signal score
984.161
Event
diarrhoea
Reports
244
Reporting signal score
322.817
Event
drug interaction
Reports
1,057
Reporting signal score
496.113
Event
drug reaction with eosinophilia and systemic symptoms
Reports
1,019
Reporting signal score
1,919.55
Event
epilepsy
Reports
622
Reporting signal score
917.36
Event
generalised tonic-clonic seizure
Reports
326
Reporting signal score
468.515
Event
lymphadenopathy
Reports
388
Reporting signal score
407.654
Event
oral mucosa erosion
Reports
121
Reporting signal score
341.13
Event
pyrexia
Reports
1,481
Reporting signal score
531.588
Event
rash
Reports
1,894
Reporting signal score
840.551
Event
rash maculo-papular
Reports
432
Reporting signal score
526.132
Event
seizure
Reports
925
Reporting signal score
919.601
Event
somnolence
Reports
792
Reporting signal score
373.3
Event
status epilepticus
Reports
264
Reporting signal score
383.54
Event
stevens-johnson syndrome
Reports
970
Reporting signal score
2,057.76
Event
suicide attempt
Reports
683
Reporting signal score
609.165
Event
toxic epidermal necrolysis
Reports
518
Reporting signal score
1,058.89
Event
toxicity to various agents
Reports
977
Reporting signal score
732.639
Event
ventricular septal defect
Reports
208
Reporting signal score
389.95

NCT00000192
clinicaltrials.gov
NCT00007670
clinicaltrials.gov
NCT00088452
clinicaltrials.gov
NCT00144872
clinicaltrials.gov
NCT00015106
clinicaltrials.gov
NCT00043875
clinicaltrials.gov
NCT00043914
clinicaltrials.gov
NCT00044278
clinicaltrials.gov
NCT00113165
clinicaltrials.gov
NCT00137709
clinicaltrials.gov
NCT00242606
clinicaltrials.gov
NCT00264615
clinicaltrials.gov
NCT00264680
clinicaltrials.gov
NCT00266149
clinicaltrials.gov
NCT00280059
clinicaltrials.gov
NCT00292461
clinicaltrials.gov
NCT00355082
clinicaltrials.gov
NCT00395694
clinicaltrials.gov
NCT00412191
clinicaltrials.gov
NCT00516139
clinicaltrials.gov
NCT00605371
clinicaltrials.gov
NCT00627575
clinicaltrials.gov
NCT00807989
clinicaltrials.gov
NCT00896987
clinicaltrials.gov
NCT01357902
clinicaltrials.gov

And 74 more, listed on the interactive page.

Hydrogen bond acceptors: 5
Hydrogen bond donors: 2
Polar surface area: 90.71
Calculated partition coefficient (ALogP): 2.01
Calculated partition coefficient (XLogP): 1.4
Prodrug: No
Chirality: Achiral
Inorganic: No
Rule-of-five violations: 0
Rotatable bonds: 1
Heavy atoms: 16
Molecular formula: C9H7Cl2N5
Monoisotopic mass: 255.0078506
Natural product: Yes

0115-1526
0115-1527
0115-1528
0115-1529
0115-9939
0115-9940
0115-9941
0115-9942
0173-0526
0173-0527
0173-0594
0173-0633
0173-0642
0173-0643
0173-0644
0173-0699
0173-0754
0173-0755
0173-0756
0173-0757
0173-0758
0173-0759
0173-0760
0173-0761
0173-0772

And 281 more, listed on the interactive page.

Recorded assays: 4,028
Active assays: 32

Confirmatory
Other
Screening

Anticonvulsants
id.nlm.nih.gov
Calcium Channel Blockers
id.nlm.nih.gov
Antipsychotic Agents
id.nlm.nih.gov
Sodium Channel Blockers
id.nlm.nih.gov

Distribution coefficient (LogD)

Median: 1.225
Mean: 1.225
Minimum: 0.54
Maximum: 1.91
Unit: unitless
Assays: 2
Standard deviation: 0.968736
Summary method: median
Censored results excluded: 0
Other units excluded: 0
Unknown units excluded: 0

Measurement types

LogD

Solubility

Median: 307,000
Mean: 307,000
Minimum: 307,000
Maximum: 307,000
Unit: nM
Assays: 1
Standard deviation: 0
Summary method: median
Censored results excluded: 0
Other units excluded: 1
Unknown units excluded: 0

Measurement types

Solubility

Oral bioavailability

Median: 79
Mean: 79
Minimum: 79
Maximum: 79
Unit: %
Assays: 1
Standard deviation: 0
Summary method: median
Censored results excluded: 0
Other units excluded: 0
Unknown units excluded: 0

Measurement types

Related records

Trials (180)

16-week Comparative Effectiveness Trial of Lamotrigine vs. Fluoxetine for Bipolar Depression
A Bioavailability Crossover Study of Two Formulations of Lamotrigine Extended Release Tablets in Healthy Subjects
A Bioequivalence Study of Two Formulations Lamotrigine 100 mg Tablets and Lamictal 100 mg Tablets in Healthy Adult Volunteers Under Fasting Conditions
A Clinical Evaluation Of BW430C (Lamotrigine) In Bipolar I Disorder- Long-term Extension Of Study SCA104779 (NCT00550407) -
A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode
A Pilot Study of Prophylactic Management of Lamotrigine in Pregnant Women
A Prospective, Observational Study On The Effectiveness Of New Antiepileptic Drugs As First Bitherapy In The Daily Clinical Practice
A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis
A Study for Evaluating the Efficacy and Safety of Zonisamide and Lamotrigine (Lamictal) for Subjects With Refractory Simple Partial, Complex Partial or Partial With Secondary Generalized Seizures
A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Caused by Ketamine
A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
A Study to Evaluate the Effect of AG-881 on the Pharmacokinetics of a Single Dose of Lamotrigine in Healthy Adults
A Study to Evaluate the Effect of Single Doses of Drug A (Lamotrigine) and Drug B (Vofopitant) Alone and in Combination on Resting Motor Threshold in Healthy Subjects
A Study to Evaluate the Effects of Lithium, Valproic Acid, and Lamotrigine on the Pharmacokinetics of KarXT and Effects of KarXT on the Pharmacokinetics of Lithium, Valproic Acid, and Lamotrigine in Healthy Participants
A Study To Investigate The Antidepressant Effect Of Lamotrigine In Patients With Bipolar Disorder Using Lithium
Acute Treatment of Bipolar II Depression
AED/Statin Interaction Study
An Evaluation Of BW430C (Lamotrigine) Versus Placebo In The Prevention Of Mood Episodes In Bipolar I Disorder Patients
An Open-Label Extension Study Of Lamotrigine In Subjects With Bipolar Disorder

Approved for (9)

Bipolar depression
Bipolar disorder
Depressive disorder
Epilepsy
Epilepsy with generalized tonic-clonic seizures
Focal epilepsy
Lennox-Gastaut syndrome
Major depressive disorder
Visual epilepsy

In development for (25)

Alcohol dependence Phase 2
Anxiety Phase 3
Childhood absence epilepsy Phase 3
Cocaine dependence Phase 2
Cognitive disorder Phase 1
Dementia Phase 3
Drug dependence Phase 2
Eating disorder Phase 3
Fish eye disease Phase 1
HIV infectious disease Phase 1
Meniere disease Phase 2
Mental disorder Phase 1
Mood disorder Phase 3
Multiple sclerosis Phase 2
Neurofibromatosis type 1 Phase 2
Neurotic excoriation Phase 2
Obesity disorder Phase 3
Opiate dependence Phase 2
Peripheral neuropathy Phase 3
Post-traumatic stress disorder Phase 3

Targets (10)

SCN10A Sodium channel alpha subunit blocker
SCN11A Sodium channel alpha subunit blocker
SCN1A Sodium channel alpha subunit blocker
SCN2A Sodium channel alpha subunit blocker
SCN3A Sodium channel alpha subunit blocker
SCN4A Sodium channel alpha subunit blocker
SCN5A Sodium channel alpha subunit blocker
SCN7A Sodium channel alpha subunit blocker
SCN8A Sodium channel alpha subunit blocker
SCN9A Sodium channel alpha subunit blocker

Lamotrigine

Development status

Names and chemistry

Brand names (10)

Other names (84)

Identifiers

Regulatory information

United States

Other regulatory facts

Approval status

Pharmacology

Drug classification

Administration routes

Mechanisms of action (10)

Open Targets mechanisms

DrugCentral mechanisms (8)

Investigated indications (32)

Open Targets indications (64)

Warnings

Open Targets warnings

Reported adverse events (25)

Trial references (99)

Chemical properties

National Drug Codes

Evidence counts

Active assay types (3)

Pharmacologic actions

Biological measurements

Observed measurements

Distribution coefficient (LogD)

Measurement types

Solubility

Measurement types

Oral bioavailability

Measurement types

Related records

Trials (180)

Approved for (9)

In development for (25)

Other linked conditions (5)

Targets (10)